Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Investigational Allo-HSCT for Advanced Hematologic Malignancies

February 23rd 2024

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

Acalabrutinib/Axi-Cel Generates Preliminary Responses in Relapsed/Refractory B-Cell Lymphoma

February 23rd 2024

Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.

IO-202 Receives FDA Orphan Drug Designation for CMML

February 22nd 2024

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

Future Landscape of Chronic GVHD

February 22nd 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

Emerging Agents in GVHD: Axatilimab

February 22nd 2024

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

FDA Grants Orphan Drug Designation to Ocifisertib for Acute Myeloid Leukemia

February 21st 2024

The FDA granted an orphan drug designation to ocifisertib for use as a potential therapeutic option in patients with acute myeloid leukemia.

ESA Treatment Selection in MDS

February 20th 2024

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia

February 20th 2024

Hematologist-oncologists address adverse event management and discuss the unmet needs of patients with lower-risk MDS and symptomatic anemia.

Additional Data Updates from ASH 2023

February 20th 2024

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

Treatment Sequencing of Later Line Therapies in R/R DLBCL

February 20th 2024

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

Bridging Therapy With CAR T-Cell Therapy in LBCL

February 20th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20th 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

February 20th 2024

Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.

Treating VOD: Standard-of-Care Approach

February 19th 2024

Mitchell Cairo, MD, shares his standard-of-care approach to treating VOD and the role of defibrotide, the only FDA-approved drug for VOD.

A Multidisciplinary Approach to Managing VOD

February 19th 2024

Sergio Giralt, MD, leads a discussion on the importance of a multidisciplinary team approach in caring for patients with VOD, from recognizing early signs to treating and monitoring the disease.

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Hematologists and Patients Come Together for Patient-Focused GVHD Discussions

February 17th 2024

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

February 16th 2024

Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.

Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

February 16th 2024

Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.

The Role of Allo-HSCT in Higher-Risk MDS

February 16th 2024

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.